This is a case report of a 28 year male who had a heart transplant due to end stage heart failure. Post operatively he developed an hyperinflammatory response and renal dysfunction, so CytoSorb was initiated together with SLED (sustained low-efficiency dialysis). In total he had 3 cycles of CytoSorb of 6 – 12 hours each. With the use of CytoSorb his hemodynamic picture improved, showing – in comparison to before and after CytoSorb therapy: mean arterial pressure 90 v 100 mmHg, norepinephrine 8 v 4.7 mg/min, dobutamine 4.5 v 0 ml/hour and vasopressin 2 v 1.5 ml/hour. His inflammatory parameters also improved, procalcitonin decreased from 169 to 34 ng/dL, and C-reactive protein 13.7 to 6 mg/dL. The tacrolimus levels were regularly monitored and no modifications were needed. Generally there were no adjustments made to his immunosuppressive therapy because of the use of CytoSorb and the patient showed no signs of rejection either clinically or with biopsy. The patient gradually recovered his renal function and was able to be discharged from intensive care and then hospital. The authors state that use of CytoSorb prevented clinical deterioration and helped to regain control of the hyperinflammation resulting in a relatively short ICU and hospital stay, reducing the financial burden.
- Case Study
- Heart Transplant
- Post-Transplant
- CytoSorb®
- 2020